海报:ALL-351 Inotuzumab Ozogamicin治疗复发/难治性(R/R) ph阳性急性淋巴性白血病(ALL)伴髓外疾病:我们的经验

{"title":"海报:ALL-351 Inotuzumab Ozogamicin治疗复发/难治性(R/R) ph阳性急性淋巴性白血病(ALL)伴髓外疾病:我们的经验","authors":"M. Dragoescu, A. Ghiaur, D. Coriu","doi":"10.1016/s2152-2650(23)00399-3","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":10370,"journal":{"name":"Clinical Lymphoma Myeloma and Leukemia","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"POSTER: ALL-351 Inotuzumab Ozogamicin in the Treatment of Relapsed/Refractory (R/R) Ph-Positive Acute Lymphoid Leukemia (ALL) With Extramedullary Disease: Our Experience\",\"authors\":\"M. Dragoescu, A. Ghiaur, D. Coriu\",\"doi\":\"10.1016/s2152-2650(23)00399-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":10370,\"journal\":{\"name\":\"Clinical Lymphoma Myeloma and Leukemia\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Lymphoma Myeloma and Leukemia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/s2152-2650(23)00399-3\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lymphoma Myeloma and Leukemia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/s2152-2650(23)00399-3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}